Curcumin Improves Mental Ability
Curcumin associated with significant memory improvement in elderly according to meta-analysis
Six clinical trials with a total of 289 subjects met inclusion criteria for this review. For older adults who received curcumin, scores on measures of cognitive function (SMD = 0.33), and measures of depression (SMD = -0.29) indicated significant memory improvement. Curcumin appears to be more effective in improving cognitive function in the elderly than in improving symptoms of Alzheimer’s disease. Curcumin is also safe and tolerated among these individuals.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2730804/
Curcumin increases BDNF, which is associated with improvement in learning, memory and behavioral disorders, according to meta-analysis
The reduction of brain-derived neurotrophic factor (BDNF) affects cognitive function, learning, and memory and also causes behavioral disorders. Four randomized control trials with 139 participants were included. Curcumin supplementation dose and duration ranged from 200 to 1820 mg/d and 8 to 12 weeks, respectively. Curcumin supplementation significantly increased serum BDNF levels (weighted mean difference: 1789.38 pg/mL). The significant positive impact of curcumin supplementation on BDNF levels indicates its potential use for neurological disorders that are associated with low BDNF levels.
https://pubmed.ncbi.nlm.nih.gov/31279955/
Curcumin improves memory and attention in older healthy adults; may reduce amyloid and tau accumulation in brain
Forty subjects (age 51-84 years) were randomized to a bioavailable form of curcumin (Theracurmin® containing 90 mg of curcumin twice daily) or placebo for 18 months. Long-Term Retrieval improved with curcumin (ES = 0.63) but not with placebo. Curcumin also improved Selective Reminding Test Total (ES = 0.53), visual memory (Recall: ES = 0.50; Delay: ES = 0.51), and attention (ES = 0.96) compared with placebo. Conclusions: Daily oral Theracurmin may lead to improved memory and attention in non-demented adults. The PET findings suggest that symptom benefits are associated with decreases in amyloid and tau accumulation in brain regions modulating mood and memory.
https://pubmed.ncbi.nlm.nih.gov/29246725/
Curcumin Improves Mental Health
Curcumin has “large effect” on anxiety and depression in meta-analysis; well tolerated
Curcumin is the principal curcuminoid found in turmeric (Curcuma longa), a spice frequently used in Asian countries. Given its anti-inflammatory and antioxidant properties, it has been hypothesized that curcumin might be effective in treating symptoms of a variety of neuropsychiatric disorders, such as depression. We found an overall significant effect of curcumin on depressive (10 studies, 531 participants, Hedge’s g = -0.75) and anxiety symptoms (5 studies, 284 participants, Hedge’s g = -2.62), with large effect size. Curcumin was generally well-tolerated by patients. Our findings suggest that curcumin, if added to standard care, might improve depressive and anxiety symptoms in people with depression.
https://pubmed.ncbi.nlm.nih.gov/31423805/
Curcumin significantly reduces depression symptoms according to meta-analysis, duration enhances effects
Six clinical trials met the inclusion criteria. Overall, curcumin administration showed a significantly higher reduction in depression symptoms [SMD = -0.34]. Subgroup analyses showed that curcumin had the highest effect when given to middle-aged patients (SMD = -0.36), for longer duration of administration (SMD = -0.40), and at higher doses (SMD = -0.36). The administration of new formulation of curcumin (BCM-95) had non-significantly higher effect on depression as compared with the conventional curcumin-piperine formula. We conclude that there is supporting evidence that curcumin administration reduces depressive symptoms in patients with major depression.
https://pubmed.ncbi.nlm.nih.gov/26610378/
Curcumin Improves Markers of Heart Disease and Metabolic Disorder
Turmeric and curcumin improves LDL cholesterol and triglycerides in meta-analysis; no serious adverse events
The analysis included 7 eligible studies (649 patients). Turmeric and curcumin significantly reduced serum LDL-C (SMD = -0.340) and triglycerides (SMD = -0.214) levels as compared to those in the control group. These may be effective in lowering serum total cholesterol levels in patients with metabolic syndrome (SMD = -0.934), and turmeric extract could possibly have a greater effect on reducing serum total cholesterol levels (SMD = -0.584). Serum HDL-C levels were not obviously improved. Turmeric and curcumin appeared safe, and no serious adverse events were reported in any of the included studies. Conclusions: Turmeric and curcumin may protect patients at risk of cardiovascular disease through improving serum lipid levels. Curcumin may be used as a well-tolerated dietary adjunct to conventional drugs.
https://pubmed.ncbi.nlm.nih.gov/29020971/
Curcumin has favorable effect on cholesterol, insulin resistance, fatty liver disease according to meta-analysis
After excluding irrelevant records, 9 randomized controlled trials included in this meta-analysis. Pooled results of included studies indicated a significant reduction in alanine transaminase (ALT), aspartate transaminase (AST), serum total cholesterol (TC), low density lipoprotein (LDL), fasting blood sugar, HOMA-IR, serum insulin and waist circumference, but not in serum triglyceride, high density lipoprotein (HDL), HbA1c, body weight and body mass index (BMI) following curcumin supplementation. Additionally, age- and baseline total cholesterol-based subgroup analysis indicated a significant reduction in triglyceride and also duration- and dosage-based showed a significant change in BMI. Conclusion: The current study revealed that curcumin supplementation has favorable effect on metabolic markers and anthropometric parameters in patients with non-alcoholic fatty liver disease.
https://pubmed.ncbi.nlm.nih.gov/31987259/
Curcumin improves fasting glucose, triglycerides, cholesterol and blood pressure in metabolic syndrome according to meta-analysis
Seven trials met the eligibility criteria. The results showed significant improvement of fasting blood glucose, triglycerides, high-density lipoprotein cholesterol, and diastolic blood pressure levels. Curcumin was not associated with a significant change in waist circumference measurement and systolic blood pressure level. Curcumin supplementation improves some components of metabolic syndrome.
https://pubmed.ncbi.nlm.nih.gov/30941814/
Curcumin/Turmeric improves blood pressure when taken long term in meta-analysis
A total of 11 studies comprising 734 participants were eligible and included in the meta-analysis to estimate pooled effect size. Subgroup analysis revealed a significant reduction only in systolic blood pressure levels (-1.24 mmHg) but not diastolic blood pressure in studies with ≥12-week supplementation. Conclusion: The present meta-analysis suggests that consuming curcumin/turmeric may improve systolic blood pressure when administered in long durations.
https://pubmed.ncbi.nlm.nih.gov/31647981/
Curcumin Improves Insulin Resistance and Blood Sugar Control
Curcumin significantly reduced HbA1C and fasting glucose in those with pre-diabetes and Type 2 diabetes in meta-analysis
Four trials (N = 508) and eight trials (N = 646) were eligible for the meta-analysis of individuals with prediabetes and type 2 diabetes mellitus, respectively. Curcumin significantly reduced glycosylated hemoglobin (HbA1c) in prediabetics (mean difference: -0.9%). Furthermore, T2DM subjects gained favorable reduction in both HbA1c (MD: -0.5%) and fasting plasma glucose (MD: -11.7 mg/dL). Tendency of lipid profile improvement was also observed.
https://pubmed.ncbi.nlm.nih.gov/31013312/
Curcumin prevents prediabetes from progressing to type 2 diabetes, reduces insulin resistance
This randomized, double-blinded, placebo- controlled trial included subjects (n = 240) with criteria of prediabetes. All subjects were randomly assigned to receive either curcumin or placebo capsules for 9 months. Results: After 9 months of treatment, 16.4% of subjects in the placebo group were diagnosed with T2DM, whereas none were diagnosed with T2DM in the curcumin-treated group. In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (61.58 vs. 48.72) and lower C-peptide (1.7 vs. 2.17). The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04) and higher adiponectin (22.46 vs. 18.45) when compared with the placebo group. Conclusions: A 9-month curcumin intervention in a prediabetic population significantly lowered the number of prediabetic individuals who eventually developed T2DM. In addition, the curcumin treatment appeared to improve overall function of β-cells, with very minor adverse effects.
https://pubmed.ncbi.nlm.nih.gov/22773702/
Curcumin Reduces Weight
Curcumin reduced BMI by 0.34 and waist circumference by 2 cm in meta-analysis
Eight randomized controlled trials with 520 participants (curcumin group = 265 and placebo group = 255) were included. Supplementation dose and duration ranged from 70 to 3,000 mg/day and 8 to 12 weeks, respectively. Curcumin supplementation significantly reduced BMI (weighted mean difference = -0.34 kg/m2) and waist circumference (weighted mean difference = -2.12 cm). These results suggest that curcumin supplementation might have a positive effect on visceral fat and abdominal obesity that have been associated with non-alcoholic fatty liver disease.
https://pubmed.ncbi.nlm.nih.gov/31799714/
Curcumin reduced body weight 1.14 kg and BMI 0.48 in meta-analysis
Totally, 11 studies that enrolled 876 subjects were included. Combining effect sizes suggested a significant effect of curcumin administration on body weight (Weighed Mean Difference (WMD): -1.14 kg) and BMI (WMD: -0.48 kg/m2), respectively. However, no significant effect of curcumin supplementation on waist circumference was found (WMD: -1.51 cm). Based on subgroup analysis, we found that the effect of curcumin on waist circumference was significant in studies that prescribed ≥1000 mg/d curcumin, those with the intervention duration of ≥8 weeks, and those that was performed on overweight subjects. Conclusions: We found a significant effect of curcumin supplementation on body weight and BMI, but not on waist circumference.
https://pubmed.ncbi.nlm.nih.gov/30373373/
Curcumin Has Anti-Cancer Effects
Curcumin suppresses initiation, progression and metastasis in a variety of tumors, according to review
Curcumin, a polyphenolic compound derived from turmeric (Curcumin longa), is one such agent that has been extensively studied over the last three to four decades for its potential anti-inflammatory and/or anti-cancer effects. Curcumin has been found to suppress initiation, progression, and metastasis of a variety of tumors. These anti-cancer effects are predominantly mediated through its negative regulation of various transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic molecules. It also abrogates proliferation of cancer cells by arresting them at different phases of the cell cycle and/or by inducing their apoptosis.
https://pubmed.ncbi.nlm.nih.gov/25665066/
Curcumin has anti-cancer effect by affecting tumor angiogenesis and growth, according to review
Curcumin exerts its anti-cancer effect by suppressing the initiation, progression, and metastasis of a variety of cancers and appears to inhibit carcinogenesis by affecting two main processes: angiogenesis and tumor growth. These anti-cancer effects are largely mediated via negative regulation of various transcription factors, growth factors, inflammatory cytokines, protein kinases, and other oncogenic molecules. The PI3K/AKT pathway is commonly activated in cancer initiation and progression. Considered to be the key signaling pathway, the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) pathway therefore represents a key target for cancer therapeutics.
https://pubmed.ncbi.nlm.nih.gov/29693253/
Curcumin speeds up death of cancer cells in colorectal cancer
The present study aims to examine the inhibitory mechanism of curcumin on cancer cells in patients with colorectal cancer. The results showed that curcumin administration increased body weight, decreased serum TNF-alpha levels, increased apoptotic tumor cells, enhanced expression of p53 molecule in tumor tissue, and modulated tumor cell apoptotic pathway. We conclude that the curcumin treatment improves the general health of patients with colorectal cancer via the mechanism of increased p53 molecule expression in tumor cells and consequently speeds up tumor cell apoptosis.
https://pubmed.ncbi.nlm.nih.gov/21314329/
Curcumin Helps with Allergies and Asthma
Curcumin improves nasal symptoms and immune response in allergic rhinitis
Curcumin alleviated nasal symptoms (sneezing and rhinorrhea) and nasal congestion through reduction of nasal airflow resistance. Curcumin was found to exert diverse immunomodulatory effects, including suppression of IL-4, IL-8, and tumor necrosis factor α and increased production of IL-10 and soluble intercellular adhesion molecule. Conclusion: This pilot study provides the first evidence of the capability of curcumin of improving nasal airflow and modulating immune response in patients with allergic rhinitis.
https://pubmed.ncbi.nlm.nih.gov/27789120/
Curcumin leads to better control of asthma over time
We conducted a randomized, double-blind, placebo-controlled, phase II clinical trial. Patients were randomly assigned to receive 30 mg/kg/day of Curcumin longa for 6 months, or placebo. All patients were categorized for asthma severity and control according to GINA-2016 and underwent pulmonary function tests. Results: Overall, both groups experienced amelioration of their frequency of symptoms and interference with normal activity, but no differences were found between the two treatment groups. However, patients receiving C. longa experienced less frequent nighttime awakenings, less frequent use of short-acting β-adrenergic agonists, and better disease control after 3 and 6 months.
https://pubmed.ncbi.nlm.nih.gov/30991137/
Curcumin Helps with Arthritis
1000 mg/day of curcumin as effective as pain medicine for arthritis in meta-analysis
We systemically evaluated all RCTs of turmeric extracts and curcumin for treating arthritis symptoms to elucidate the efficacy of curcuma for alleviating the symptoms of arthritis. A pain visual analogue score (PVAS) and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) were used for the major outcomes of arthritis. Initial searches yielded 29 articles, of which 8 met specific selection criteria. Three among the included RCTs reported reduction of PVAS (mean difference: -2.04) with turmeric/curcumin in comparison with placebo, whereas meta-analysis of four studies showed a decrease of WOMAC with turmeric/curcumin treatment (mean difference: -15.36). Furthermore, there was no significant mean difference in PVAS between turmeric/curcumin and pain medicine in meta-analysis of five studies. In conclusion, these RCTs provide scientific evidence that supports the efficacy of turmeric extract (about 1000 mg/day of curcumin) in the treatment of arthritis.
https://pubmed.ncbi.nlm.nih.gov/27533649/
Curcumin treats osteoarthritis effectively, with less side effects than ibuprofen, according to meta-analysis
A total of 5 studies with 599 patients were included in this study. The results showed that curcumin could significantly improve the WOMAC score (SMD=-0.96) and VAS score of osteoarthritis patients (SMD=-1.65). Furthermore, the side effect rate of curcumin treatment was 0.81 times that of ibuprofen treatment. Curcumin can treat osteoarthritis patients effectively, improving WOMAC score and VAS score, and the side effect of curcumin was not higher than that of ibuprofen.
https://pubmed.ncbi.nlm.nih.gov/30772789/
Curcumin may be as effective as NSAIDs on knee osteoarthritis, as safe as placebo, according to meta-analysis
Eleven random controlled trials (N = 1009) were eligible for analysis. Both curcuminoid and boswellia formulations were statistically significantly more effective than placebo for pain relief and functional improvement. There were no significant differences between curcuminoids or boswellia and placebo in safety outcomes. Curcuminoids showed no statistically significant differences in efficacy outcomes compared to NSAIDs; patients receiving curcuminoids were significantly less likely to experience gastrointestinal adverse events.
https://pubmed.ncbi.nlm.nih.gov/29622343/
Curcumin Reduces Pain
Curcumin significantly reduces pain; is safe and well tolerated in meta-analysis
A total of eight randomized controlled trials met our inclusion criteria that included 606 randomized patients. Curcuminoids were found to significantly reduce pain (standard mean difference: -0.57). This pain-relieving effect was found to be independent of administered dose and duration of treatment with curcuminoids, and was free from publication bias. Curcuminoids were safe and well tolerated in all evaluated randomized controlled trials. Conclusion: Curcuminoids supplements may be a safe and effective strategy to improve pain severity.
https://pubmed.ncbi.nlm.nih.gov/26814259/
Curcumin Beneficial in Autoimmune Disease
Curcumin benefits several autoimmune disorders by regulating inflammation, according to review
Recent studies have shown that curcumin ameliorates multiple sclerosis, rheumatoid arthritis, psoriasis, and inflammatory bowel disease in human or animal models. Curcumin inhibits these autoimmune diseases by regulating inflammatory cytokines such as IL-1beta, IL-6, IL-12, TNF-alpha and IFN-gamma and associated JAK-STAT, AP-1, and NF-kappaB signaling pathways in immune cells.
https://pubmed.ncbi.nlm.nih.gov/17569223/
Curcumin reduces markers of autoimmune disease in multiple sclerosis
Our analysis revealed that the proportions of Th17 were increased dramatically, along with increases in the levels of IL-17A, IL-23, and RORγt expression in multiple sclerosis patients in compared with healthy control group. Post-treatment evaluation of the nanocurcumin group revealed a significant decrease in Th17 associated parameters such as Th17 frequency, expression levels of RORγt and IL-17 and also secretion level of IL-17. However, in the placebo group there is no significant changes in these factors. Conclusion: Our study suggests that the increase in proportion of Th17 cells might contribute to the pathogenesis of RRMS. The results of the current work indicated that nanocurcumin is able to restore the dysregulated of Th17 cells in MS patients.
https://pubmed.ncbi.nlm.nih.gov/29852475/
Curcumin May Reduce Severity of Viral Illness
Curcumin reduces severity of influenza in mice, may prevent lung injury
Curcumin, an active phenolic agent extract from the Curcuma longa, exhibits excellent anti-cancer, anti-inflammation, and neuroprotective effects. We aimed to investigate the anti-influenza role of curcumin in vitro and in vivo. Curcumin could inhibit influenza A in vitro and alleviate the severity of the disease in the mouse after infection with influenza A. Furthermore, curcumin could regulate immune response following influenza A infection through inhibiting production of local inflammatory cytokines. Our current study supports the potential of curcumin as a promising treatment against influenza A infection, whose effect may be mediated by regulating immune response to prevent injury to the lung tissue.
https://pubmed.ncbi.nlm.nih.gov/28853207/
Curcumin has potential to treat COVID-19 with its antiviral effects, according to review
Curcumin, as an active constituent of Curcuma longa (turmeric), has been studied in several experimental and clinical trial studies. Curcumin has some useful clinical effects such as antiviral, antinociceptive, anti-inflammatory, antipyretic, and antifatigue effects that could be effective to manage the symptoms of the infected patient with COVID-19. It has several molecular mechanisms including antioxidant, antiapoptotic, and antifibrotic properties with inhibitory effects on Toll-like receptors, NF-κB, inflammatory cytokines and chemokines, and bradykinin. Scientific evidence suggests that curcumin could have a potential role to treat COVID-19.
https://pubmed.ncbi.nlm.nih.gov/33133525/
Curcumin May Extend Lifespan
Curcumin extends lifespan in animals; lower doses may be preferable to high
There are plenty of examples to support the possible anti-ageing role of curcumin. Curcumin supplementation in a diet extended the lifespan of fruit flies, nematodes and mice. Moreover, in clinical trials, curcumin was proven to reduce symptoms of some age-related diseases such as atherosclerosis, diabetes and cancer. It also serves as a neuroprotective agent. Curcumin is involved in the regulation of nutrient-sensing signaling pathways (impact on sirtuins, AMPK), and thus it is able to mimic caloric/diet restriction and increase the benefits coming from mild physical activity. Our own data shown that curcumin anti-ageing function results neither from its anti-senescent nor senolytic function, even though curcumin is able to modulate cellular senescence. Low doses activated sirtuins and AMPK, which are considered as having anti-senescent properties, but cytostatic doses inhibited sirtuins and AMPK, inducing, in this manner, cellular senescence.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6429134/
Curcumin Reduces Inflammation
Curcumin reduces inflammatory markers according to meta-analysis
Fifteen randomized controlled trials were included in the final analysis. The meta-analysis indicated that curcumin supplementation significantly decreased interleukin 6 (IL-6) (SMD -2.08), high-sensitivity C-reactive protein (hs-CRP) (SMD -0.65), and malondialdehyde (MDA) concentrations (SMD -3.14). Though, curcumin supplementation had no significant effect on tumor necrosis factor-alpha and superoxide dismutase levels. Overall, this meta-analysis suggests that taking curcumin-containing supplements may exert anti-inflammatory and antioxidant properties through a significant reduction in IL-6, hs-CRP, and MDA levels.
https://pubmed.ncbi.nlm.nih.gov/30402990/
Curcumin significantly reduces inflammation marker CRP, associated with cardiovascular disease, in meta-analysis
Inflammation plays a pivotal role in the pathogenesis of atherosclerosis and cardiovascular disease. In this context, C-reactive protein (CRP) has been identified as a strong predictor and independent risk factor of cardiovascular disease. Six trials comprising 172 subjects in the curcuminoids group and 170 subjects in the placebo group fulfilled the eligibility criteria and included in the meta-analysis. Compared with placebo, supplementation with curcuminoids was associated with a significant reduction in circulating CRP levels (weighed mean difference: -6.44 mg/L). This significant effect was maintained in subgroups of trials that used bioavailability-improved preparations of curcuminoids and had supplementation duration of ≥4 weeks, but not in the subgroups without these characteristics. Conclusions: Supplementation with curcuminoids may reduce circulating CRP levels. This effect appears to depend on the bioavailability of curcuminoids preparations and also duration of supplementation. Future well-designed and long-term trials are warranted to verify this effect of curcuminoids.
https://pubmed.ncbi.nlm.nih.gov/23922235/
Curcumin significantly reduces inflammation marker IL-6 according to meta-analysis
Nine randomized controlled trials comprising 10 treatment arms were found to be eligible for the meta-analysis. There was a significant reduction of circulating IL-6 concentrations following curcuminoids supplementation (weighted mean difference: -0.60pg/mL). Meta-regression did not suggest any significant association between the circulating IL-6 lowering effects of curcuminoids with either dose or duration of treatment. There was a significant association between the IL-6-lowering activity of curcumin and baseline IL-6 concentration (slope: -0.51). This meta-analysis suggested a significant effect of curcumin in lowering circulating IL-6 concentrations. This effect appears to be more evident in patients with higher degrees of systemic inflammation.
https://pubmed.ncbi.nlm.nih.gov/27392742/
Curcumin increases production of a natural anti-inflammatory and improves related conditions according to review
IL-10 deregulation plays a role in the development of a large number of inflammatory diseases such as neuropathic pain, Parkinson’s disease, Alzheimer’s disease, osteoarthritis, rheumatoid arthritis, psoriasis, systemic lupus erythematosus, type 1 diabetes, inflammatory bowel disease, and allergy. Curcumin is a natural anti-inflammatory compound able to induce the expression and production of IL-10 and enhancing its action on a large number of tissues. In vitro and in pre-clinical models curcumin is able to modulate the disease pathophysiology of conditions such as pain and neurodegenerative diseases, bowel inflammation, and allergy, but also of infections and cancer through its effect on IL-10 secretion.
https://pubmed.ncbi.nlm.nih.gov/28799796/
Benefit of turmeric and curcumin on inflammatory markers did not reach statistical significance in meta-analysis
We performed a systematic review of randomized controlled trials evaluating the effects of oral turmeric or curcumin on inflammatory markers (CRP, hsCRP, IL-1, IL-6, TNF) in patients with a wide range of chronic inflammatory diseases. Nineteen trials were identified; included patients had rheumatic diseases, advanced chronic kidney disease with hemodialysis, metabolic syndrome, and cardiovascular diseases. Turmeric was the intervention in 5 trials (n = 356) and curcumin/curcuminoids in 14 trials (n = 988). Follow up times ranged between 4 and 16 weeks. In comparison to controls, turmeric or curcumin did not significantly decrease levels of CRP, hsCRP, IL-1 beta, IL-6, and TNF alpha. There were no differences between turmeric and curcumin interventions. Turmeric or curcumin did not decrease several inflammatory markers in patients with chronic inflammatory diseases. (Note that all findings trended towards benefit, though not statistically significant due to sample size.)
https://pubmed.ncbi.nlm.nih.gov/31121255/
Curcumin significantly improves markers of oxidative stress in meta-analysis
Oxidative stress is associated with aging and multiple diseases, yet the effects of curcumin in humans are not definite. We undertook a meta-analysis of the effects of curcumin on oxidative stress biomarkers. The meta-analysis included eight clinical studies (626 patients). There was a significant reduction in circulating serum malondialdehyde (MDA) concentrations (SMD = -0.769) and a significant increase in superoxide dismutase (SOD) activity (SMD = 1.084) following curcumin supplementation. There was no change in the glutathione peroxidase activity in RBC. There was no significant association between the MDA-lowering effect of curcumin with underlying diseases or treatment duration. However, curcumin showed the MDA-lowering effect at curcuminoids doses ≥600 mg/d. This effect was greater when combined with piperine than curcuminoids alone (SMD = -1.085; SMD = -0.850). Curcumin may play an anti-oxidative role by reducing circulating MDA concentrations and increasing SOD activity.
https://pubmed.ncbi.nlm.nih.gov/30527253/
Curcumin Appears Safe, But No Conclusion on Dosing or Formulation
Curcumin found safe, tolerable at doses up to 8 g per day according to review
As discussed in this review, curcumin has shown therapeutic potential against a number of human diseases. Common to all of these studies have been the safety, tolerability, and non-toxicity of this polyphenol, even at doses up to 8 g per day. The underlying mechanism for curcumin’s clinical efficacy seems to be modulation of numerous signaling molecules. However, because of the complex nature of the diseases, the underlying mechanism in many cases remains unclear.
[This article shares dosing info for numerous studies]
School Appears Safe During COVID-19, According to Research
Leave a Reply